Molecular subtypes, including the human epidermal growth factor receptor 2-enriched subtype (HER2+), drive patient outcomes in human breast cancer but the biological basis underlying subtype-specific disease is not completely understood (1-4). We mined published microarray data (5, 6) to discover in an unbiased fashion the most distinguishing genetic and transcriptional features of tumors of each breast cancer molecular subtype. We identified a single nucleotide polymorphism, rs8079797,

more »

... within USP32, as among the most significant genetic differences in the tumors of patients with HER2+ breast cancer. In a separate cohort of patients with HER2+ subtype breast cancer, we failed to observe differential expression of a USP32 transcript. Analysis of patient survival data revealed that USP32 primary tumor expression was correlated with recurrence-free survival in patients with human breast cancer. Sequence variation in the USP32 gene may be important in understanding differences in genetic background that favor development of HER2+ subtype human breast cancer.